These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9597161)

  • 1. In vitro and in vivo drug interactions involving human CYP3A.
    Thummel KE; Wilkinson GR
    Annu Rev Pharmacol Toxicol; 1998; 38():389-430. PubMed ID: 9597161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
    Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics. SNP-ing drugs to size.
    Gura T
    Science; 2001 Jul; 293(5530):595. PubMed ID: 11474082
    [No Abstract]   [Full Text] [Related]  

  • 7. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
    Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
    Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition.
    Wienkers LC
    Eur J Pharm Sci; 2002 Apr; 15(3):239-42. PubMed ID: 11923055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression.
    Paolini M; Pozzetti L; Piazza F; Guerra MC; Speroni E; Cantelli-Forti G; Roda A
    J Investig Med; 2000 Jan; 48(1):49-59. PubMed ID: 10695269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
    Ma B; Prueksaritanont T; Lin JH
    Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y; Benet LZ
    Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C; Kim RB; Guengerich FP; Wood AJ
    Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prehepatic metabolism of drugs--a mechanism for low and variable oral bioavailability.
    Hoppu K
    Pediatr Nephrol; 1999 Jan; 13(1):85-9. PubMed ID: 10100297
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.